McKesson Corporation $MCK Shares Purchased by Dana Investment Advisors Inc.

Dana Investment Advisors Inc. boosted its holdings in shares of McKesson Corporation (NYSE:MCK) by 4.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 23,272 shares of the company’s stock after buying an additional 928 shares during the quarter. Dana Investment Advisors Inc.’s holdings in McKesson were worth $17,979,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the business. J.W. Cole Advisors Inc. lifted its stake in shares of McKesson by 35.3% in the third quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock valued at $3,931,000 after purchasing an additional 1,329 shares during the period. Private Wealth Partners LLC raised its holdings in McKesson by 5.6% in the 3rd quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock valued at $24,598,000 after acquiring an additional 1,682 shares during the last quarter. AlphaQuest LLC increased its stake in McKesson by 91.2% during the third quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock worth $1,365,000 after acquiring an additional 843 shares during the last quarter. CW Advisors LLC raised its stake in shares of McKesson by 282.5% in the 2nd quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock valued at $8,067,000 after acquiring an additional 8,130 shares during the period. Finally, Envestnet Asset Management Inc. raised its holdings in shares of McKesson by 12.4% during the 3rd quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock valued at $255,438,000 after buying an additional 36,451 shares during the period. 85.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at McKesson

In related news, EVP Leann B. Smith sold 190 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total value of $179,550.00. Following the transaction, the executive vice president directly owned 2,989 shares in the company, valued at $2,824,605. This trade represents a 5.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the firm’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $955.00, for a total transaction of $313,240.00. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 1,143 shares of company stock worth $1,046,070. 0.08% of the stock is owned by insiders.

McKesson Trading Up 0.0%

Shares of McKesson stock opened at $947.58 on Tuesday. McKesson Corporation has a 1-year low of $598.58 and a 1-year high of $971.93. The company has a market cap of $116.07 billion, a PE ratio of 27.25, a price-to-earnings-growth ratio of 1.53 and a beta of 0.40. The company has a 50 day moving average of $856.14 and a 200-day moving average of $798.99.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The business had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.McKesson’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Research analysts forecast that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 annualized dividend and a yield of 0.3%. McKesson’s dividend payout ratio (DPR) is currently 9.43%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MCK shares. UBS Group upped their price objective on McKesson from $920.00 to $980.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. JPMorgan Chase & Co. upped their price objective on shares of McKesson from $983.00 to $1,107.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Robert W. Baird set a $968.00 target price on shares of McKesson in a research report on Wednesday, January 14th. Wells Fargo & Company increased their price target on shares of McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a report on Thursday, February 5th. Finally, Barclays lifted their price objective on McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Thirteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $943.50.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.